Search

Displaying results 3751 - 3760 of 5898 in total
  1. Drug

    CX501

    go.drugbank.com/drugs/DB05174
    Investigational

    Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of

  2. Drug

    LIC-477

    go.drugbank.com/drugs/DB05363
    Experimental

    LIC-477is indicated to be suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia and cerebral spasticity.

  3. Drug

    Lancovutide

    go.drugbank.com/drugs/DB05029
    Investigational

    Lancovutide is a 19-amino-acid tetracyclic peptide produced by Streptoverticillium cinnamoneus and is closely related to cinnamycin (Ro09-0198). It belongs to the lantibiotics.

  4. Drug

    IMM-101

    go.drugbank.com/drugs/DB15850
    Investigational

    Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help kill cancer cells. … It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma[A220013,A220018,A220023].

  5. Drug

    LY-517717

    go.drugbank.com/drugs/DB05713
    Investigational

    It is believed to be Lilly's PMD-3112 (licensed from Amgen).

  6. Drug

    Bevantolol

    go.drugbank.com/drugs/DB01295
    Investigational

    Bevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. … Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors.

  7. Drug

    GI-5005

    go.drugbank.com/drugs/DB05942
    Investigational

    GI-5005 is whole, heat-killed recombinant yeast genetically modified to express HCV-specific protein targets. … Tarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response.

  8. Drug

    Cedirogant

    go.drugbank.com/drugs/DB18951
    Investigational

    Cedirogant is under investigation in clinical trial NCT05044234 (A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis

  9. Drug

    NRP369

    go.drugbank.com/drugs/DB06384
    Experimental

    NRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].

  10. Drug

    Nordazepam

    go.drugbank.com/drugs/DB14028
    Investigational

    An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.